Corcept Therapeutics (CORT) Inspires Confidence with ROSELLA Phase 3 Survival Data [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
On April 11, Corcept Therapeutics Inc. (NASDAQ:CORT) released the overall survival results from its Phase 3 ROSELLA study involving Lifyorli and nab-paclitaxel treatment for women with platinum-resistant ovarian cancer during the annual conference of the Society of Gynaecologic Oncology. The findings were concurrently published in The Lancet journal. The ROSELLA study achieved both of its primary objectives of overall survival and progression-free survival without compromising on safety. This backs our bullish views for the stock. Copyright: katrintimoff / 123RF Stock Photo The combination of Lifyorli with nab-paclitaxel is now part of the National Comprehensive Cancer Network guidelines as a preferred treatment regimen. The drug received approval from the FDA in March 2026 for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients receiving Lifyorli with nab-paclitaxel showed 35% fewer chances of mortality. Median overall
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORTGlobeNewswire
- Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud LawsuitPR Newswire
- 1 Cash-Producing Stock for Long-Term Investors and 2 We Ignore [Yahoo! Finance]Yahoo! Finance
- Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026Business Wire
CORT
Earnings
- 2/24/26 - Miss
CORT
Sec Filings
- 4/24/26 - Form 4
- 4/21/26 - Form SCHEDULE
- 4/17/26 - Form DEF
- CORT's page on the SEC website